MA46266B1 - Formes cristallines - Google Patents
Formes cristallinesInfo
- Publication number
- MA46266B1 MA46266B1 MA46266A MA46266A MA46266B1 MA 46266 B1 MA46266 B1 MA 46266B1 MA 46266 A MA46266 A MA 46266A MA 46266 A MA46266 A MA 46266A MA 46266 B1 MA46266 B1 MA 46266B1
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline forms
- crystal forms
- pharmaceutical compositions
- phosphono
- pyrrolidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
L'invention concerne des formes cristallines de chlorhydrate d'ester butylique 4- ( r )-2-{[6- (( s )-3-méthoxy-pyrrolidin-1-yl)-2-phényl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-pipérazine-1-carboxylique, des procédés pour leur préparation, des compositions pharmaceutiques comprenant lesdites formes cristallines, des compositions pharmaceutiques préparées à partir de telles formes cristallines et leur utilisation en tant que médicament, en particulier en tant qu'antagoniste du récepteur p2y 12 .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016072562 | 2016-09-22 | ||
| PCT/EP2017/073858 WO2018055016A1 (fr) | 2016-09-22 | 2017-09-21 | Formes cristallines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46266A MA46266A (fr) | 2019-07-31 |
| MA46266B1 true MA46266B1 (fr) | 2022-02-28 |
Family
ID=59923448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46266A MA46266B1 (fr) | 2016-09-22 | 2017-09-21 | Formes cristallines |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10730896B2 (fr) |
| EP (2) | EP3981774A1 (fr) |
| JP (1) | JP7097369B2 (fr) |
| KR (1) | KR102552795B1 (fr) |
| CN (1) | CN109715639B (fr) |
| AU (1) | AU2017331930B2 (fr) |
| CA (1) | CA3037794A1 (fr) |
| CL (1) | CL2019000728A1 (fr) |
| CY (1) | CY1125052T1 (fr) |
| DK (1) | DK3515924T3 (fr) |
| EA (1) | EA201990723A1 (fr) |
| ES (1) | ES2908572T3 (fr) |
| HR (1) | HRP20220234T1 (fr) |
| HU (1) | HUE057772T2 (fr) |
| IL (1) | IL265445B2 (fr) |
| LT (1) | LT3515924T (fr) |
| MA (1) | MA46266B1 (fr) |
| MX (1) | MX381590B (fr) |
| MY (1) | MY193080A (fr) |
| PH (1) | PH12019500567B1 (fr) |
| PL (1) | PL3515924T3 (fr) |
| PT (1) | PT3515924T (fr) |
| RS (1) | RS62946B1 (fr) |
| SI (1) | SI3515924T1 (fr) |
| TW (1) | TWI752086B (fr) |
| UA (1) | UA124073C2 (fr) |
| WO (1) | WO2018055016A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE057772T2 (hu) | 2016-09-22 | 2022-06-28 | Idorsia Pharmaceuticals Ltd | Kristályos formák |
| US11179390B2 (en) | 2017-03-15 | 2021-11-23 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a P2Y12 receptor antagonist |
| DK4181872T3 (da) | 2020-07-15 | 2026-01-26 | Viatris Asia Pacific Pte Ltd | Vandig, farmaceutisk sammensætning omfattende en p2y12 receptorantagonist |
| MX2024000653A (es) * | 2021-07-13 | 2024-01-31 | Idorsia Pharmaceuticals Ltd | Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| CA2020437A1 (fr) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Derive de cinnamamide |
| US6855715B1 (en) | 1999-06-14 | 2005-02-15 | Eli Lilly And Company | Serine protease inhibitors |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| CA2507657C (fr) | 2002-12-11 | 2011-05-31 | Bayer Schering Pharma Aktiengesellschaft | Composes de 2-aminocarbonyl-quinoline utilises en tant qu'antagonistes du recepteur de l'adenosine diphosphate des plaquettes |
| PT1611144E (pt) | 2003-04-09 | 2010-11-12 | Wyeth Llc | Derivados do ácido 2-(8,9-dioxo-2,6-diazabiciclo(5.2.0)- non-1(7)-eno-2-il)-alquil-fosfónico e sua utilização como antagonistas do receptor n-metil-d-aspartato (nmda) |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| ES2421448T3 (es) | 2005-10-21 | 2013-09-02 | Actelion Pharmaceuticals Ltd | Derivados de piperazina como agentes contra la malaria |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| CL2007003038A1 (es) | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| CA2684644A1 (fr) | 2007-04-23 | 2008-10-30 | Sanofi-Aventis | Derives de quinoleine-carboxamide comme antagonistes de p2y12 |
| BRPI0819696B1 (pt) | 2007-11-29 | 2018-10-23 | Actelion Pharmaceuticals Ltd | compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto |
| JP5504171B2 (ja) | 2007-12-26 | 2014-05-28 | サノフイ | Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド |
| JP5560202B2 (ja) | 2007-12-26 | 2014-07-23 | サノフイ | Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体 |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| WO2010116328A2 (fr) | 2009-04-08 | 2010-10-14 | Actelion Pharmaceuticals Ltd | 6-(3-azabicyclo[3.1.0]hex-3-yl)-2-phénylpyrimidines |
| KR101728180B1 (ko) | 2009-04-22 | 2017-04-18 | 액테리온 파마슈티칼 리미티드 | 티아졸 유도체들 및 ｐ2ｙ12 수용체 길항제로서 이들의 용도 |
| HUE057772T2 (hu) | 2016-09-22 | 2022-06-28 | Idorsia Pharmaceuticals Ltd | Kristályos formák |
| US11179390B2 (en) | 2017-03-15 | 2021-11-23 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a P2Y12 receptor antagonist |
| DK4181872T3 (da) | 2020-07-15 | 2026-01-26 | Viatris Asia Pacific Pte Ltd | Vandig, farmaceutisk sammensætning omfattende en p2y12 receptorantagonist |
-
2017
- 2017-09-21 HU HUE17771436A patent/HUE057772T2/hu unknown
- 2017-09-21 ES ES17771436T patent/ES2908572T3/es active Active
- 2017-09-21 MX MX2019003093A patent/MX381590B/es unknown
- 2017-09-21 CA CA3037794A patent/CA3037794A1/fr active Pending
- 2017-09-21 LT LTEPPCT/EP2017/073858T patent/LT3515924T/lt unknown
- 2017-09-21 EA EA201990723A patent/EA201990723A1/ru unknown
- 2017-09-21 PL PL17771436T patent/PL3515924T3/pl unknown
- 2017-09-21 MY MYPI2019001474A patent/MY193080A/en unknown
- 2017-09-21 MA MA46266A patent/MA46266B1/fr unknown
- 2017-09-21 JP JP2019536696A patent/JP7097369B2/ja active Active
- 2017-09-21 KR KR1020197011330A patent/KR102552795B1/ko active Active
- 2017-09-21 SI SI201731102T patent/SI3515924T1/sl unknown
- 2017-09-21 EP EP21206477.8A patent/EP3981774A1/fr not_active Withdrawn
- 2017-09-21 WO PCT/EP2017/073858 patent/WO2018055016A1/fr not_active Ceased
- 2017-09-21 TW TW106132387A patent/TWI752086B/zh active
- 2017-09-21 HR HRP20220234TT patent/HRP20220234T1/hr unknown
- 2017-09-21 CN CN201780057793.2A patent/CN109715639B/zh active Active
- 2017-09-21 PT PT177714367T patent/PT3515924T/pt unknown
- 2017-09-21 IL IL265445A patent/IL265445B2/en unknown
- 2017-09-21 PH PH1/2019/500567A patent/PH12019500567B1/en unknown
- 2017-09-21 UA UAA201903751A patent/UA124073C2/uk unknown
- 2017-09-21 AU AU2017331930A patent/AU2017331930B2/en active Active
- 2017-09-21 RS RS20220163A patent/RS62946B1/sr unknown
- 2017-09-21 US US16/335,973 patent/US10730896B2/en active Active
- 2017-09-21 EP EP17771436.7A patent/EP3515924B1/fr active Active
- 2017-09-21 DK DK17771436.7T patent/DK3515924T3/da active
-
2019
- 2019-03-21 CL CL2019000728A patent/CL2019000728A1/es unknown
-
2020
- 2020-07-24 US US16/938,730 patent/US11365209B2/en active Active
-
2022
- 2022-03-09 CY CY20221100195T patent/CY1125052T1/el unknown
- 2022-05-10 US US17/741,427 patent/US12227532B2/en active Active
-
2025
- 2025-01-17 US US19/028,423 patent/US20250163086A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54091A (fr) | Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr | |
| MX2021004000A (es) | Derivados de piperidina. | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| EP4616908A3 (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3693369A3 (fr) | Inhibiteurs de bromodomaine | |
| EP2076244A4 (fr) | Systèmes aqueux pour la préparation de composés pharmaceutiques à base lipidique et leurs compositions, procédés et utilisations | |
| MX382649B (es) | Análogos de pridopidina, su preparación y uso. | |
| MD20160012A2 (ro) | Formulare de inhibitori SYK | |
| MX394588B (es) | Composición farmacéutica. | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA37742A1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
| MA39163B1 (fr) | Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine | |
| EP3526203A4 (fr) | Dérivés de n-aryle et de n-hétéroaryle pipéridine en tant qu'agonistes des récepteurs bêta x du foie, compositions et utilisation associées | |
| JOP20170197B1 (ar) | الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول | |
| EP3248603A4 (fr) | Composition pharmaceutique destinée à la prévention, au traitement ou au ralentissement de la maladie d'alzheimer ou de la démence contenant un agent de type récepteur couplé à une protéine g 19 comme principe actif | |
| WO2018193090A3 (fr) | Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci | |
| CY1125052T1 (el) | Κρυσταλλικες μορφες | |
| MX2017015961A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
| NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
| EP3612167A4 (fr) | Procédé de préparation d'une forme posologique à désintégration orale | |
| EP4342542A3 (fr) | Combinaison d'inhibiteurs de régorafénib et de pd-1/pd-l1(2) pour le traitement du cancer | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| BR112018073410A2 (pt) | combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| WO2015138276A3 (fr) | Modulateurs du récepteur orphelin lié au récepteur de l'acide rétinoïque et leurs utilisations |